Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clinuvel Pharmaceuticals ( (AU:CUV) ) has provided an announcement.
Clinuvel Pharmaceuticals has announced the cessation of 46,067 performance rights, which lapsed after the applicable conditions for conversion into securities were not met or became incapable of being satisfied. The move slightly reduces the company’s pool of potential equity-based remuneration and may marginally affect future dilution expectations for existing shareholders, but does not alter the current issued capital or operational activities.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$27.90 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals is a biopharmaceutical company listed on the ASX, focused on developing and commercialising therapies, including pharmaceutical formulations, for disorders related to the skin and pigmentation. The company targets niche indications where there are significant unmet medical needs and maintains its primary market presence in Australia with global investor interest.
Average Trading Volume: 110,374
Technical Sentiment Signal: Sell
Current Market Cap: A$460.9M
See more insights into CUV stock on TipRanks’ Stock Analysis page.